SeaStar Medical Holding Corporation is asking stockholders to vote at its virtual 2026 annual meeting on four key items. Stockholders will elect one Class I director, John Neuman, to serve until the 2029 annual meeting, and vote on an expanded equity plan.
The company seeks approval to amend and restate its 2022 Equity Incentive Plan to increase authorized common shares under the plan from 207,046 to 896,546, following a 1-for-10 reverse stock split effective January 5, 2026. Stockholders will also vote on ratifying WithumSmith+Brown, PC as independent auditor for 2026 and on a possible adjournment of the meeting if more time is needed to gather votes. As of April 24, 2026, 3,997,002 shares of common stock were outstanding and entitled to one vote per share.
SeaStar Medical Holding Corporation is filing an S-1 to register the resale of up to 1,664,543 shares of common stock held by Lincoln Park Capital Fund LLC. These shares relate to a previously signed $15.0 million equity purchase agreement, under which SeaStar can periodically sell stock to Lincoln Park.
SeaStar will not receive proceeds from Lincoln Park’s resale of these registered shares, but may receive up to an additional $14,657,887.43 in gross proceeds from future share sales to Lincoln Park under the agreement. As of April 20, 2026, the company had 3,997,002 shares outstanding, and sales under this structure, alongside past at-the-market offerings, could dilute existing holders.
The filing also describes SeaStar’s commercial-stage inflammatory disease platform, including its FDA-approved pediatric SCD therapy under a Humanitarian Device Exemption, multiple Breakthrough Device Designations, and ongoing adult clinical programs targeting acute kidney injury and cardiorenal indications.
SeaStar Medical Holding Corporation reports that a previously filed federal securities class action against the company and certain executives has been dismissed with prejudice. The lawsuit, filed in 2024, had alleged misstatements or omissions related to the company’s business, operations and a prior financial restatement.
After the parties submitted a stipulation of dismissal on April 21, 2026, the United States District Court for the District of Colorado ordered on April 27, 2026 that the case be dismissed with prejudice. This ruling closes the putative class action without the option for the same claims to be refiled.
SeaStar Medical Holding Corporation is a commercial-stage healthcare company developing its Selective Cytopheretic Device (SCD) to treat life‑threatening hyperinflammatory conditions that drive acute and chronic organ failure. The SCD modulates over‑active neutrophils and monocytes via an extracorporeal membrane integrated into continuous renal replacement therapy systems.
In February 2024, the FDA approved the pediatric SCD therapy QUELIMMUNE under a Humanitarian Device Exemption for acute kidney injury due to sepsis, and commercial shipments began in July 2024. As of December 31, 2025, 10 hospitals had completed the required SAVE Surveillance Registry and purchased QUELIMMUNE, with early registry data in 21 patients showing no device‑related safety events and favorable 60‑ and 90‑day survival.
For adults, the pivotal NEUTRALIZE‑AKI trial in ICU patients with acute kidney injury on CRRT targets 339 subjects, with 181 enrolled as of March 21, 2026. The SCD platform has received multiple FDA Breakthrough Device Designations across acute kidney injury, cardiorenal and hepatorenal syndromes, end‑stage renal disease, and cardiac surgery–related systemic inflammation, supported by a patent estate of 17 U.S. and 29 foreign patents.
SeaStar Medical Holding Corporation reported much stronger 2025 results as it ramps commercialization of its QUELIMMUNE therapy. Net revenue rose to approximately $420 thousand in the fourth quarter from $67 thousand a year earlier, and to about $1.23 million for 2025 versus $135 thousand in 2024, reflecting a first full year of QUELIMMUNE sales and initial SCD research revenue. Quarterly net loss narrowed to roughly $2.9 million from $4.4 million, while full-year net loss improved to around $12.2 million from $24.8 million. Cash increased to $12.0 million as of December 31, 2025, compared with $1.8 million a year earlier. The company highlighted business progress, including adding top-ranked children’s hospitals to the QUELIMMUNE customer base, completing enrollment in the QUELIMMUNE SAVE pediatric post-marketing registry, surpassing the 50% enrollment milestone in the NEUTRALIZE-AKI pivotal trial in adults with acute kidney injury, and initiating a cardio-renal clinical trial using its Selective Cytopheretic Device therapy.
SeaStar Medical Holding Corp received an updated ownership report from investors Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC. As of December 31, 2025, they report beneficial ownership of 3,980,665 shares of common stock, equal to 9.99% of the class.
The position is entirely through six warrants held by Intracoastal. Three warrants are counted, while three additional warrants are contractually blocked from exercise above 9.99% or 4.99% ownership caps. Without these blocker provisions, their beneficial ownership would be 5,342,845 shares. The group states the holdings are not for changing or influencing control of SeaStar Medical.
SeaStar Medical Holding Corp director Kenneth Van Heel reported receiving a grant of restricted stock units (RSUs) under the company’s equity program. On February 6, 2026, he acquired 3,000 shares of common stock at a price of $0 as an award.
According to the filing, these RSUs will vest in full on February 6, 2027, meaning the shares become fully owned on that date if vesting conditions are met. After this grant, Van Heel beneficially owns 7,940 shares of SeaStar Medical common stock directly.
SeaStar Medical Holding Corp director John Neuman reported a stock-based award. On February 6, 2026, he received 3,000 shares of common stock at a stated price of $0, reported as an acquired transaction.
After this grant, Neuman beneficially owns 12,200 shares of SeaStar Medical common stock in direct form. The filing notes that the 3,000-share award represents restricted stock units (RSUs) that will vest in full on February 6, 2027.
SeaStar Medical Holding Corp director Vincent Bernadette N reported receiving 3,000 shares of common stock on February 6, 2026 under transaction code A, indicating an acquisition. The filing notes this represents a restricted stock unit (RSU) award that will vest in full on February 6, 2027. The shares were acquired at a stated price of $0 per share, leaving the director with 4,200 shares of beneficially owned common stock held directly after the grant.